About KEYTRUDA in metastatic colorectal cancer (CRC)
KEYTRUDA® (pembrolizumab) in metastatic colorectal cancer (CRC)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
KEYTRUDA as monotherapy is indicated for:
|Metastatic colorectal cancer|
|For use in||The first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults1|
|Dosing schedule||The recommended dose is either 200 mg every 3 weeks or 400 mg every 6 weeks, administered as an intravenous infusion over 30 minutes1|
|Treat until disease progression or unacceptable toxicity1|
|Clinical trial||KEYNOTE-177 was a Phase 3, multicentre, open-label, active-controlled study of adult patients with metastatic MSI-H/dMMR colorectal cancer, randomised 1:1 to receive pembrolizumab or investigator’s choice of chemotherapy regimens2|
Click here to download the KEYNOTE-177 clinical data presentation
- KEYTRUDA Summary of Product Characteristics.
- André T, Shiu K-K, Kim TW, et al. N Engl J Med. 2020;383:2207-2218.
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website